Gilat Satellite Networks Ltd.

Shares of Israeli satellite communications company Gilat, which are traded on the Nasdaq, could rise almost 20% over the next two months, according to an investment idea put out by Freedom Broker (and seen by Oninvest). The selloff following the company’s latest earnings has created an attractive entry point, while rising tensions in the Middle East are boosting demand for the company’s products, the analysts said.

Freedom sees attractive entry point in satellite maker Gilat amid geopolitical morass

Centerra Gold Inc.

NovaGold Resources Inc.

Gold Royalty Corp.

Contango Ore, Inc.

Caledonia Mining Corporation Plc

Dakota Gold Corp.

Galiano Gold Inc.

DRDGOLD Limited

Insider Monkey has <a href="https://www.insidermonkey.com/blog/12-best-gold-stocks-to-buy-according-to-analysts-1706769/5/">identified</a>&nbsp;12 gold mining companies that Wall Street analysts consider attractive "buys." Eight of them are small- or mid-cap firms.

Insider Monkey picks best smid-cap gold stocks amid continuing rally in yellow metal

Krispy Kreme, Inc.

Shares of doughnut maker Krispy Kreme <a href="https://www.marketwatch.com/investing/stock/dnut/analystestimates?mod=mw_quote_tab">surged</a>&nbsp;27.8% after the company released its fourth-quarter and full-year financial results. The company said it expects further deleveraging and progress in executing its turnaround plan following the <a href="https://en.oninvest.com/article/krispy-kreme-and-mcdonald-s-will-end-their-doughnut-partnership-analysts-were-betting-on-it">end of its partnership with McDonald’s</a>.

Krispy Kreme shares shoot up almost 30% on 4Q/FY earnings

Bajaj Consumer Care Limited

MTAR Technologies Limited

MRV Engenharia e Participacoes S.A.

Last year showed that small caps in emerging markets can compete with large issuers, despite a <a href="https://en.oninvest.com/article/undervalued-small-caps-where-to-make-money-in-emerging-markets">lag</a>&nbsp;that persisted through the third quarter. For 2025, the return of the Equal Weight EM Small Cap Index, put together by analyst Aldiyar Anuarbekov for Oninvest, amounted to 18.25% in dollar terms*. For comparison: the broad-market S&amp;P 500 index grew 16.65%, while the smid-cap Russell 2000 rose 11.21% last year. The 8.06% increase in the Cap Weight EM Small Cap Index, meanwhile, indicates that the gains were more evenly distributed rather than concentrated in a small number of large stocks.

Where to find outstripping returns in EM small caps in 2026

Dutch Bros Inc.

Dutch Bros, a small U.S. coffee chain, is a growth stock that "could supercharge your returns over the next five years and beyond," <a href="https://www.fool.com/investing/2026/02/26/growth-stock-supercharge-invest-return-5-years/">argues</a>&nbsp;Motley Fool contributing analyst Neil Patel. The company’s stock is trading about 45% below its peak even as its fundamentals remain strong, he says, creating an attractive entry point for investors.

Motley Fool analyst likes growing U.S. coffee chain Dutch Bros on dip

VolitionRx Limited

Shares of VolitionRx, a micro-cap developer of blood tests for cancer and sepsis, <a href="https://finance.yahoo.com/quote/VNRX/">jumped</a>&nbsp;nearly 26% on Tuesday after the company <a href="https://ir.volition.com/news-events/press-releases/detail/874/volitionrx-highlights-commercial-momentum-and-multi-pillar-execution">reported</a>&nbsp;progress in several research programs and said a newly developed cancer-detection method has attracted interest from potential partners. The company also highlighted breakthrough research on detecting lymphoma in cats. Wall Street analysts <a href="https://www.marketwatch.com/investing/stock/vnrx/analystestimates?mod=mw_quote_tab">say</a>&nbsp;the stock could have nearly 790% upside.

Cancer blood test maker VolitionRX soars 25% in a day on reported commercial progress

PicS N.V.

BofA Securities has <a href="https://www.cnbc.com/2026/02/24/tuesday-stocks-by-analyst-calls-like-nvidia.html">initiated</a>&nbsp;coverage of Brazilian fintech PicPay with a “buy” rating, less than a month after the company <a href="https://filemanager-cdn.mziq.com/published/f4269298-97ef-427d-ac29-04f9d6a6054a/590c0052-1dc9-410c-9c7d-0d8615ae5783_picpay_pricing_press_release.pdf">went public</a> in an IPO, listing on the Nasdaq. The company’s earnings per share is expected to grow at an average annual rate of 117% through 2028, with the main driver being an expansion of PicPay's loan portfolio, BofA <a href="https://www.investing.com/news/analyst-ratings/bofa-securities-initiates-picpay-stock-with-buy-rating-on-credit-growth-93CH-4521017">said</a>.

BofA is latest to initiate on Brazilian digital bank PicPay at 'buy'

Vir Biotechnology, Inc.

Shares of Vir Biotechnology, a small-cap developer of drugs for infectious diseases and cancer, <a href="https://finance.yahoo.com/quote/VIR/">soared</a>&nbsp;on Tuesday by almost 28% to reach their highest level in more than a year. The company provided a series of updates, which were described as amounting to a “<a href="https://investors.vir.bio/news/news-details/2026/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx">seminal moment</a>” for Vir. They include, among other things, a <a href="https://investors.vir.bio/news/news-details/2026/Astellas-and-Vir-Biotechnology-Announce-Global-Strategic-Collaboration-to-Advance-PSMA-targeting-PRO-XTEN-Dual-masked-T-Cell-Engager-VIR-5500-for-the-Treatment-of-Prostate-Cancer/default.aspx">partnership</a>&nbsp;with Japan’s Astellas worth up to $1.71 billion. Against this backdrop, several investment banks <a href="https://finance.yahoo.com/quote/VIR/">raised</a>&nbsp;their target prices for Vir stock.

'Seminal moment': Biotech Vir sees shares jump over 25% amid flurry of announcements

AS MADARA Cosmetics

The Baltic States – Lithuania, Latvia, and Estonia – are emerging from an economic downturn. According to the European Commission forecasts, the region is now entering a phase of moderate growth, with the key driver being a recovery in domestic demand. Against this backdrop, Baltic companies, whose shares are illiquid but which are stable in terms of fundamentals, can offer a risk premium in a segment that remains off large investors' radar and lacks broad analytical coverage. Marius Varneckas, head of Freedom24 in Lithuania, argues that this is creating attractive entry points for investors in 2026.

Freedom24-Lithuania head shares Baltic small-cap stocks and sectors with 2026 upside

York Space Systems, Inc.

Eight Wall Street analysts have <a href="https://www.marketwatch.com/investing/stock/yss/analystestimates?mod=mw_quote_tab">initiated coverage</a> of York Space Systems, recommending shares of the low-cost satellite maker less than a month after it <a href="https://ir.yorkspacesystems.com/news/news-details/2026/York-Space-Systems-Announces-Pricing-of-Upsized-Initial-Public-Offering/default.aspx">went public</a> on the New York Stock Exchange. The company is heavily reliant on government funding and major defense initiatives such as Trump’s Golden Dome missile defense program for the U.S. homeland, but Wall Street appears willing to accept that risk, Barron’s <a href="https://www.barrons.com/articles/york-space-systems-stock-ratings-26467d20?mod=RTA">believes</a>.

Eight analysts initiate on space stock York with 'buy' following recent IPO

Arcellx, Inc.

Gilead Sciences, Inc.

Shares of Arcellx, a mid-cap developer of cell therapies for blood cancers, <a href="https://finance.yahoo.com/quote/ACLX/">surged</a>&nbsp;77% on Monday to a new all-time high after the <a href="https://ir.arcellx.com/news/news-details/2026/Gilead-Sciences-to-Acquire-Arcellx-to-Maximize-Long-term-Potential-of-Anito-cel/default.aspx">announcement</a>&nbsp;that its major partner, Gilead Sciences, will acquire the company at a substantial premium to the market price. For investors, the deal signals that leading pharmaceutical companies increasingly prefer full ownership of late-stage oncology assets, Noble <a href="https://www.channelchek.com/news-channel/gilead-to-acquire-arcellx-in-7-8b-bet-on-next-gen-car-t-leadership">argues</a>.

Cancer drugmaker Arcellx explodes 77% in a day as Gilead will acquire it

Lucid Group, Inc.

Investors should avoid buying shares of electric vehicle maker Lucid in the hope of a rebound, <a href="https://www.fool.com/investing/2026/02/22/should-you-buy-lucid-while-its-below-10/">argues</a>&nbsp;Motley Fool contributor Chris Neiger. Over the past three years, the company’s stock has fallen about 90%, a decline that may make the shares look attractive ahead of the planned launch of a lower-priced EV model. But that appeal is misleading, the analyst believes, the core issue being that Lucid remains deeply unprofitable.

Small caps